Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number

J Thorac Oncol. 2013 Dec;8(12):e105-6. doi: 10.1097/JTO.0b013e3182a00e37.

Authors

Sara Pilotto¹, Emilio Bria, Umberto Peretti, Francesco Massari, Marina Garassino, Giuseppe Pelosi, Giampaolo Tortora

Affiliation

¹ *Medical Oncology, Azienda Ospedaliera Universitaria Integrata, University of Verona, Verona, Italy; and Departments of †Medical Oncology and ‡Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale Tumori and Università degli Studi, Milan, Italy.

PMID: 24389444
DOI: 10.1097/JTO.0b013e3182a00e37

No abstract available

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Adenocarcinoma / drug therapy*
Adenocarcinoma / genetics
Adenocarcinoma / pathology
Aged
Anaplastic Lymphoma Kinase
Antineoplastic Agents / pharmacology
Crizotinib
DNA, Neoplasm / genetics
Drug Resistance, Neoplasm / drug effects*
ErbB Receptors / genetics*
Female
Gefitinib
Gene Dosage*
Humans
In Situ Hybridization, Fluorescence
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics
Lung Neoplasms / pathology
Mutation / genetics*
Prognosis
Protein Kinase Inhibitors / therapeutic use
Protein-Tyrosine Kinases / genetics*
Proto-Oncogene Proteins / genetics*
Proto-Oncogene Proteins c-met / genetics*
Pyrazoles / therapeutic use*
Pyridines / therapeutic use*
Quinazolines / pharmacology*
Receptor Protein-Tyrosine Kinases / genetics*
Salvage Therapy

Substances

Antineoplastic Agents
DNA, Neoplasm
Protein Kinase Inhibitors
Proto-Oncogene Proteins
Pyrazoles
Pyridines
Quinazolines
Crizotinib
ALK protein, human
Anaplastic Lymphoma Kinase
EGFR protein, human
ErbB Receptors
MET protein, human
Protein-Tyrosine Kinases
Proto-Oncogene Proteins c-met
ROS1 protein, human
Receptor Protein-Tyrosine Kinases
Gefitinib